

Specimen ID:
Control ID:

Acct #: 17452095 Phone: (800) 539-6119 Rte: 00
Walk-In Lab, LLC
1645 Tiffany Lane
Mandeville, LA 70448

Patient Details

DOB:
Age(y/m/d):
Gender: SSN:
Patient ID:

Specimen Details

Date collected:
Date entered:
Date reported:

Physician Details

Ordering: L CHANDLER
Referring:
ID: 1043330921
NPI: 1043330921

General Comments & Additional Information

Alternate Control Number:
Total Volume: Not Provided

Alternate Patient ID: Not Provided
Fasting: Yes

Ordered Items

ASH FibroSure; Drawing Fee

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
ASH FibroSure					
ASH FibroSURE Results:					01
Fibrosis Score	0.11			0.00 - 0.21	01
Fibrosis Stage					01
	F0 - No fibrosis				01
Steatosis Score	0.53	High		0.00 - 0.30	01
Steatosis Grade					01
	S1 - S2 Minimal Steatosis - Moderate Steatosis				01
ASH Score	0.00			0.00 - 17.00	01
ASH Grade					01
	H0 - No ASH				01
Analysis:					01
Height:	72		Inches		01
Weight:	200		LBS		01
Alpha 2-Macroglobulins, Qn	121		mg/dL	110 - 276	01
Haptoglobin	166		mg/dL	34 - 200	01
Apolipoprotein A-1	159		mg/dL	101 - 178	01
Bilirubin, Total	0.9		mg/dL	0.0 - 1.2	01
GGT	49		IU/L	0 - 65	01
ALT (SGPT) P5P	43		IU/L	0 - 55	01
AST (SGOT) P5P	34		IU/L	0 - 40	01
Cholesterol, Total	258	High	mg/dL	100 - 199	01
Glucose, Serum	97		mg/dL	65 - 99	01
Triglycerides	119		mg/dL	0 - 149	01
Interpretation:					01

Quantitative results of 10 biochemicals in combination with age, gender, height and weight, are analyzed using a computational

Patient:
DOB:

Patient ID:

Control ID:

Specimen ID:
Date collected:

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
-------	--------	------	-------	--------------------	-----

algorithm to provide a quantitative surrogate marker (0.0-1.0) of liver fibrosis (Metavir F0-F4), hepatic steatosis (0.0-1.0, S0-S3), and Alcoholic Steato-Hepatitis (ASH) (0.0-1.0, H0-H3).
 Fibrosis Marker: In a study of 221 alcoholic patients where 63% had significant alcoholic fibrosis (Metavir F2-F4) and 31% had cirrhosis by liver biopsy, a fibrosis result of >0.3 yielded a sensitivity of 84% and a specificity of 66% for the detection of significant fibrosis. A fibrosis result of >0.7 yielded a sensitivity of 91% and a specificity of 87% for detection of cirrhosis(1).
 Steatosis Marker: In a population of 744 patients (583 HCV, 18 HBV, 69 NAFLD, and 74 alcoholic disease patients), where 36% had significant steatosis (>5%) on a liver biopsy, a steatosis score >0.5 had a sensitivity of 71% and a specificity of 72% for identification of significant steatosis(2).
 ASH Marker: In a population of 225 alcoholic patients where 34% had alcoholic hepatitis features (polynuclear neutrophil infiltrate and hepatocellular necrosis) by liver biopsy, an Alcoholic Steato-Hepatitis value >0.5 had a sensitivity of 80% and a specificity of 84% in identifying alcoholic steato-hepatitis(3).

Fibrosis Scoring:

- <0.21 = Stage F0 - No fibrosis
- 0.21 - 0.27 = Stage F0 - F1
- 0.27 - 0.31 = Stage F1 - Portal fibrosis
- 0.31 - 0.48 = Stage F1 - F2
- 0.48 - 0.58 = Stage F2 - Bridging fibrosis with few septa
- 0.58 - 0.72 = Stage F3 - Bridging fibrosis with many septa
- 0.72 - 0.74 = Stage F3 - F4
- >0.74 = Stage F4 - Cirrhosis

01

Steatosis Grading

- < 0.30 = S0 - No Steatosis
- 0.30 to 0.38 = S0 - S1
- 0.38 to 0.48 = S1 - Minimal Steatosis
- 0.48 to 0.57 = S1 - S2
- 0.57 to 0.67 = S2 - Moderate Steatosis
- 0.67 to 0.69 = S2 - S3
- > 0.69 = S3 - Marked or Severe Steatosis

01

ASH Scoring

- < 0.1700 = H0 - No ASH
- 0.1700 to 0.5535 = H1 - Mild ASH
- 0.5535 to 0.7800 = H2 - Moderate ASH
- > 0.7800 = H3 - Severe ASH

01

Limitations:

ASH FibroSure is recommended for patients with suspected alcoholic liver disease. It is not recommended for patients with other liver diseases. It is also not recommended in patients with Gilbert Disease, acute hemolysis, acute viral hepatitis, drug induced hepatitis, genetic liver disease, autoimmune hepatitis, and/or extra-hepatic cholestasis. Any of these clinical situations may lead to inaccurate quantitative predictions of fibrosis.

01

Comment:

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug

01

Patient:
DOB:

Patient ID:

Control ID:

Specimen ID:
Date collected:

TESTS	RESULT	FLAG	UNITS	REFERENCE	INTERVAL	LAB
-------	--------	------	-------	-----------	----------	-----

Administration. The FDA has determined that such clearance or approval is not necessary. For questions regarding this report please contact customer service at 1-800-788-9223.

References:

1. Naveau S. et al. Biomarkers for the Prediction of Liver Fibrosis in Patients with Chronic Alcoholic Liver Disease. Clinical Gastroenterol. / Hepatol. 2005;3:167-174.
2. Poynard, T. et al. The Diagnostic Value of Biomarkers (Steato Test) for the Prediction of Liver Steatosis. Comparative Hepatol. 2005; 4:10.
3. Thabut D. et al. The Diagnostic Value of Biomarkers (Ash Test) for the Prediction of Alcoholic Steato-hepatitis in Patients with Chronic Alcoholic Liver Disease. J Hepatol. 2006;44:1175-85.

01	BN	LabCorp Burlington 1447 York Court, Burlington, NC 27215-3361	Dir: William F Hancock, MD
----	----	--	----------------------------

For inquiries, the physician may contact **Branch: 504-828-2666 Lab: 800-762-4344**